A promising study, LumoKaunas2023, is underway in Lithuania to evaluate the Lumoral device's effectiveness in treating severe periodontitis (stages III-IV). Launched in August 2023, this clinical study in Kaunas, Lithuania, aims to investigate whether regular use of Lumoral, a light-activated antibacterial treatment developed by Finnish scientists, can benefit patients with advanced gum disease. The study is led by Associate Professor Ingrida Pacauskiené and involves a team of experienced dental researchers.

The Lumoral device, which combines a specialised antibacterial mouthwash with dual-light therapy, has already shown positive results in previous studies (eg HOPE-CP1) for managing early-stage periodontitis. LumoKaunas2023, now including 38 of its target 60 participants, builds on these findings by exploring the device's potential for more severe cases.

Periodontitis, a common yet serious disease, can lead to tooth loss and systemic health complications if left untreated. Studies show that Lumoral's antibacterial effects reduce harmful plaque bacteria, supporting traditional oral hygiene practices and lowering infection risk. Three-month results from the HOPE-CP study show that 54% (N = 59) of Lumoral users had healthy gums based on the BOP (bleeding on probing) index, compared to just 22% in the control group.

Meanwhile, the research also shows that two out of three (67%) participants who used the device were able to reduce the number of deep gum pockets by half compared to the initial situation, while four participants were able to eradicate deep gum pockets completely. The results are significantly better than those of the participants in the control group.

The LumoKaunas2023 study, expected to finish by early autumn 2025, highlights a shift toward preventive care and marks an important step toward more effective treatments that support oral health and reduce the effects of severe gum disease.